Cascadian Therapeutics Stock Price, News & Analysis (NASDAQ:CASC)

$9.99 0.00 (0.00 %)
(As of 02/16/2018 04:00 PM ET)
Previous Close$9.99
Today's Range$9.97 - $10.00
52-Week Range$3.18 - $10.21
Volume990,228 shs
Average Volume2.00 million shs
Market Capitalization$505.68 million
P/E Ratio-7.40
Dividend YieldN/A
Beta3.96

About Cascadian Therapeutics (NASDAQ:CASC)

Cascadian Therapeutics logoCascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Receive CASC News and Ratings via Email

Sign-up to receive the latest news and ratings for CASC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CASC
CUSIP68232410
Phone206-801-2100

Debt

Debt-to-Equity RatioN/A
Current Ratio11.86%
Quick Ratio11.86%

Price-To-Earnings

Trailing P/E Ratio-7.39994518559122
Forward P/E Ratio-7.87
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.30 per share
Price / Book3.03

Profitability

Trailing EPS($1.35)
Net Income$-57,700,000.00
Net MarginsN/A
Return on Equity-41.50%
Return on Assets-39.04%

Miscellaneous

Employees57
Outstanding Shares50,620,000

Cascadian Therapeutics (NASDAQ:CASC) Frequently Asked Questions

What is Cascadian Therapeutics' stock symbol?

Cascadian Therapeutics trades on the NASDAQ under the ticker symbol "CASC."

How were Cascadian Therapeutics' earnings last quarter?

Cascadian Therapeutics Inc (NASDAQ:CASC) released its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. During the same period last year, the firm posted ($0.09) EPS. View Cascadian Therapeutics' Earnings History.

Where is Cascadian Therapeutics' stock going? Where will Cascadian Therapeutics' stock price be in 2018?

6 Wall Street analysts have issued 12-month price objectives for Cascadian Therapeutics' stock. Their forecasts range from $4.00 to $10.00. On average, they expect Cascadian Therapeutics' share price to reach $6.00 in the next twelve months. View Analyst Ratings for Cascadian Therapeutics.

What are Wall Street analysts saying about Cascadian Therapeutics stock?

Here are some recent quotes from research analysts about Cascadian Therapeutics stock:

  • 1. According to Zacks Investment Research, "Cascadian Therapeutics, Inc. is a biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer. The company's product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor which is in preclinical trial stage. Cascadian Therapeutics, Inc., formerly known as Oncothyreon Inc., is headquartered in Seattle, Washington. " (1/9/2018)
  • 2. Cantor Fitzgerald analysts commented, "Pooled analysis from Phase Ib trial in HER2+ metastatic breast cancer patients with or without brain metastases demonstrated similarity in PFS between two groups (264P), which is a secondary endpoint in the HER2CLIMB trial." (9/11/2017)
  • 3. Cowen Inc analysts commented, "CASC reported 1Q financials and provided a pipeline update." (5/9/2017)

Are investors shorting Cascadian Therapeutics?

Cascadian Therapeutics saw a decline in short interest in January. As of January 12th, there was short interest totalling 818,899 shares, a decline of 36.2% from the December 29th total of 1,282,670 shares. Based on an average trading volume of 324,030 shares, the days-to-cover ratio is currently 2.5 days. Approximately 2.0% of the shares of the stock are sold short.

Who are some of Cascadian Therapeutics' key competitors?

Who are Cascadian Therapeutics' key executives?

Cascadian Therapeutics' management team includes the folowing people:

  • Christopher S. Henney Ph.D., Chairman of the Board (Age 76)
  • Scott D. Myers, President, Chief Executive Officer, Director (Age 51)
  • Julia Marie Eastland, Chief Financial Officer, Vice President - Corporate Development, Secretary (Age 51)
  • Gary W. Christianson, Chief Operating Officer (Age 61)
  • Scott Peterson Ph.D., Chief Scientific Officer (Age 54)
  • Robert W. Azelby, Director (Age 49)
  • Gwendolyn A. Fyfe M.D., Independent Director (Age 65)
  • Steven P. James, Independent Director (Age 58)
  • Ted W. Love M.D., Independent Director (Age 58)
  • Daniel Keith Spiegelman, Independent Director (Age 58)

Who owns Cascadian Therapeutics stock?

Cascadian Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.39%), Tekla Capital Management LLC (1.46%), Goldman Sachs Group Inc. (1.31%), Redmile Group LLC (1.28%), Kennedy Capital Management Inc. (0.98%) and Geode Capital Management LLC (0.77%). Company insiders that own Cascadian Therapeutics stock include Christopher S Henney, Gwen A Fyfe, Scott Dunseth Myers and Ted W Love. View Institutional Ownership Trends for Cascadian Therapeutics.

Who sold Cascadian Therapeutics stock? Who is selling Cascadian Therapeutics stock?

Cascadian Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Deutsche Bank AG, P.A.W. Capital Corp, Perkins Capital Management Inc., Rhumbline Advisers and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Cascadian Therapeutics.

Who bought Cascadian Therapeutics stock? Who is buying Cascadian Therapeutics stock?

Cascadian Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Goldman Sachs Group Inc., Kennedy Capital Management Inc., Tekla Capital Management LLC, Essex Investment Management Co. LLC, Unterberg Capital LLC, Alps Advisors Inc. and Millennium Management LLC. Company insiders that have bought Cascadian Therapeutics stock in the last two years include Christopher S Henney, Gwen A Fyfe, Scott Dunseth Myers and Ted W Love. View Insider Buying and Selling for Cascadian Therapeutics.

How do I buy Cascadian Therapeutics stock?

Shares of Cascadian Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cascadian Therapeutics' stock price today?

One share of Cascadian Therapeutics stock can currently be purchased for approximately $9.99.

How big of a company is Cascadian Therapeutics?

Cascadian Therapeutics has a market capitalization of $505.68 million. The biopharmaceutical company earns $-57,700,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. Cascadian Therapeutics employs 57 workers across the globe.

How can I contact Cascadian Therapeutics?

Cascadian Therapeutics' mailing address is 2601 FOURTH AVENUE SUITE 500, SEATTLE WA, 98121. The biopharmaceutical company can be reached via phone at 206-801-2100 or via email at [email protected]


MarketBeat Community Rating for Cascadian Therapeutics (CASC)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  217 (Vote Outperform)
Underperform Votes:  219 (Vote Underperform)
Total Votes:  436
MarketBeat's community ratings are surveys of what our community members think about Cascadian Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cascadian Therapeutics (NASDAQ:CASC) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.332.402.402.75
Ratings Breakdown: 1 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.00$6.00$6.00$7.00
Price Target Upside: 40.36% downside67.13% upside67.13% upside81.82% upside

Cascadian Therapeutics (NASDAQ:CASC) Consensus Price Target History

Price Target History for Cascadian Therapeutics (NASDAQ:CASC)

Cascadian Therapeutics (NASDAQ:CASC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/31/2018Raymond James FinancialDowngradeOutperform -> Market PerformLowView Rating Details
9/11/2017Cantor FitzgeraldReiterated RatingHold$4.00MediumView Rating Details
9/6/2017BarclaysInitiated CoverageUnderweight$4.00HighView Rating Details
8/9/2017CowenReiterated RatingBuyHighView Rating Details
4/21/2017BTIG ResearchInitiated CoverageBuyHighView Rating Details
3/11/2017Jefferies GroupReiterated RatingBuy$15.00 -> $10.00N/AView Rating Details
(Data available from 2/17/2016 forward)

Earnings

Cascadian Therapeutics (NASDAQ:CASC) Earnings History and Estimates Chart

Earnings by Quarter for Cascadian Therapeutics (NASDAQ:CASC)

Cascadian Therapeutics (NASDAQ CASC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.29)($0.28)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.36)($0.30)ViewListenView Earnings Details
5/9/2017Q1 2017($0.39)($0.30)ViewListenView Earnings Details
3/9/2017Q4 2016($0.52)($0.47)ViewN/AView Earnings Details
11/7/2016Q3 2016($0.08)($0.09)ViewN/AView Earnings Details
8/8/2016Q2 2016($0.60)($0.36)ViewN/AView Earnings Details
5/9/2016Q1 2016($0.10)($0.14)ViewN/AView Earnings Details
3/14/2016Q4($0.08)($0.10)ViewN/AView Earnings Details
11/5/2015Q315($0.10)($0.05)ViewListenView Earnings Details
8/6/2015Q215($0.08)($0.11)ViewN/AView Earnings Details
5/11/2015Q115($0.08)($0.08)ViewListenView Earnings Details
3/10/2015Q414($0.09)($0.30)ViewListenView Earnings Details
11/6/2014Q314($0.11)($0.09)ViewN/AView Earnings Details
8/11/2014Q214($0.13)($0.09)ViewN/AView Earnings Details
5/1/2014Q114($0.12)($0.14)ViewN/AView Earnings Details
3/13/2014Q413($0.10)($0.09)ViewN/AView Earnings Details
11/12/2013Q3($0.11)($0.12)ViewListenView Earnings Details
8/6/2013Q2 2013($0.14)($0.28)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.13)($0.14)ViewN/AView Earnings Details
3/25/2013Q412$1.09$0.50$135.60 million$123.57 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.16)($0.12)ViewN/AView Earnings Details
11/28/20121.16$1.16$137.19 millionViewN/AView Earnings Details
11/7/2012Q312($0.15)($0.15)ViewN/AView Earnings Details
8/9/2012($0.15)($0.15)ViewN/AView Earnings Details
5/7/2012($0.17)$0.21ViewN/AView Earnings Details
3/6/2012($0.15)($0.27)ViewN/AView Earnings Details
11/8/2011($0.16)$0.22ViewN/AView Earnings Details
8/8/2011Q2 2011($0.90)($0.96)ViewN/AView Earnings Details
5/6/2011Q1 2011($1.08)($1.13)ViewN/AView Earnings Details
3/10/2011Q4 2010($1.20)($1.00)ViewN/AView Earnings Details
11/8/2010Q3 2010($1.02)($1.01)ViewN/AView Earnings Details
8/5/2010Q2 2010($0.78)($1.01)ViewN/AView Earnings Details
5/6/2010Q4 2009($0.53)ViewN/AView Earnings Details
11/11/2009Q3 2009($0.96)($1.45)ViewN/AView Earnings Details
8/12/2009Q2 2009($0.84)($1.10)ViewN/AView Earnings Details
5/14/2009Q1 2009($1.02)($0.76)ViewN/AView Earnings Details
3/9/2009Q4 2008$0.72$6.35ViewN/AView Earnings Details
11/6/2008Q3 2008($1.10)ViewN/AView Earnings Details
8/7/2008Q2 2008($1.38)($1.51)ViewN/AView Earnings Details
5/7/2008Q1 2008($1.32)($1.57)ViewN/AView Earnings Details
3/10/2008Q4 2007($1.98)($1.58)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Cascadian Therapeutics (NASDAQ:CASC) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.27 EPS
Next Year EPS Consensus Estimate: $-1.03 EPS

Dividends

Dividend History for Cascadian Therapeutics (NASDAQ:CASC)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Cascadian Therapeutics (NASDAQ CASC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.10%
Institutional Ownership Percentage: 80.59%
Insider Trades by Quarter for Cascadian Therapeutics (NASDAQ:CASC)
Insider Trades by Quarter for Cascadian Therapeutics (NASDAQ:CASC)

Cascadian Therapeutics (NASDAQ CASC) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/11/2017Scott Dunseth MyersInsiderBuy5,500$3.74$20,570.0049,716View SEC Filing  
5/12/2017Scott Dunseth MyersInsiderBuy2,800$4.00$11,200.0044,216View SEC Filing  
3/31/2017Scott Dunseth MyersInsiderBuy2,000$4.11$8,220.0041,416View SEC Filing  
3/28/2017Gwen A FyfeDirectorBuy1,666$4.12$6,863.923,332View SEC Filing  
3/20/2017Scott Dunseth MyersInsiderBuy1,000$3.93$3,930.0039,416View SEC Filing  
2/2/2017Ted W. LoveDirectorBuy23,000$4.24$97,520.00View SEC Filing  
1/30/2017Christopher S HenneyDirectorBuy25,324$4.11$104,081.6450,000View SEC Filing  
1/27/2017Scott Dunseth MyersInsiderBuy20,500$3.76$77,080.00View SEC Filing  
8/17/2016Scott Dunseth MyersInsiderBuy45,000$1.15$51,750.00107,500View SEC Filing  
6/28/2016Scott Dunseth MyersCEOBuy62,500$0.80$50,000.0062,500View SEC Filing  
6/1/2015Diana HausmanInsiderBuy5,747$4.65$26,723.55View SEC Filing  
3/26/2015Daniel K SpiegelmanDirectorBuy10,000$1.59$15,900.00View SEC Filing  
3/25/2015Daniel K SpiegelmanDirectorBuy10,000$1.63$16,300.00View SEC Filing  
12/17/2014Bvf Partners L P/IlMajor ShareholderBuy378,444$1.82$688,768.08View SEC Filing  
12/15/2014Bvf Partners L P/IlMajor ShareholderBuy224,949$1.88$422,904.12View SEC Filing  
9/23/2014Jay VenkatesanEVPBuy250,000$2.00$500,000.00View SEC Filing  
7/10/2014Daniel K SpiegelmanDirectorSell3,403$1.72$5,853.16View SEC Filing  
2/20/2014Daniel K SpiegelmanDirectorSell12,780$1.96$25,048.80View SEC Filing  
11/1/2013Bvf Partners L P/IlMajor ShareholderBuy129,000$1.78$229,620.00View SEC Filing  
8/8/2013Bvf Partners P/Ilmajor shareholderBuy258,361$1.65$426,295.65View SEC Filing  
8/1/2013Bvf Partners L P/IlMajor ShareholderBuy338,087$1.74$588,271.38View SEC Filing  
6/7/2013Bvf Partners L P/IlMajor ShareholderBuy214,467$1.81$388,185.27View SEC Filing  
12/27/2012Wendy W WarrenMajor ShareholderSell57,943$64.30$3,725,734.90View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cascadian Therapeutics (NASDAQ CASC) News Headlines

Source:
DateHeadline
 Analysts Expect Cascadian Therapeutics Inc (CASC) Will Post Earnings of -$0.29 Per Share Analysts Expect Cascadian Therapeutics Inc (CASC) Will Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - February 13 at 3:18 PM
Cascadian Therapeutics Inc (CASC) Receives Consensus Recommendation of "Hold" from BrokeragesCascadian Therapeutics Inc (CASC) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 10 at 3:24 AM
Analyzing Cascadian Therapeutics (CASC) and Uniqure (QURE)Analyzing Cascadian Therapeutics (CASC) and Uniqure (QURE)
www.americanbankingnews.com - February 9 at 10:12 AM
Seattle Genetics (SGEN) Commences Tender Offer for Cascadian Therapeutics (CASC)Seattle Genetics (SGEN) Commences Tender Offer for Cascadian Therapeutics (CASC)
www.streetinsider.com - February 9 at 9:14 AM
ACT NOW: Monteverde & Associates PC Announces An Investigation of Cascadian Therapeutics, Inc. - CASCACT NOW: Monteverde & Associates PC Announces An Investigation of Cascadian Therapeutics, Inc. - CASC
finance.yahoo.com - February 9 at 9:14 AM
Today’s Research Reports on Trending Tickers: Bellicum Pharmaceuticals and Cascadian TherapeuticsToday’s Research Reports on Trending Tickers: Bellicum Pharmaceuticals and Cascadian Therapeutics
finance.yahoo.com - February 9 at 9:13 AM
Today’s Research Reports on Trending Tickers: Cascadian Therapeutics and UnitedHealth GroupToday’s Research Reports on Trending Tickers: Cascadian Therapeutics and UnitedHealth Group
finance.yahoo.com - February 8 at 8:54 AM
SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Cascadian Therapeutics, Inc. - CASCSHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Cascadian Therapeutics, Inc. - CASC
finance.yahoo.com - February 7 at 9:14 AM
What Seattle Genetics Surprise Acquisition Means For The Bottom Line - Seeking AlphaWhat Seattle Genetics' Surprise Acquisition Means For The Bottom Line - Seeking Alpha
seekingalpha.com - February 4 at 9:08 AM
Investors Buy Large Volume of Cascadian Therapeutics Call Options (CASC)Investors Buy Large Volume of Cascadian Therapeutics Call Options (CASC)
www.americanbankingnews.com - February 4 at 1:06 AM
Wired News – Seattle Genetics to Acquire Cascadian TherapeuticsWired News – Seattle Genetics to Acquire Cascadian Therapeutics
finance.yahoo.com - February 2 at 9:11 AM
Cascadian Therapeutics Target of Unusually Large Options Trading (CASC)Cascadian Therapeutics Target of Unusually Large Options Trading (CASC)
www.americanbankingnews.com - February 2 at 1:16 AM
Cascadian Therapeutics (CASC) Earnings Growth Limit RatingCascadian Therapeutics (CASC) Earnings Growth Limit Rating
investorplace.com - February 1 at 10:12 AM
CASCADIAN THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of BuyoutCASCADIAN THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
finance.yahoo.com - February 1 at 9:15 AM
Cascadian Therapeutics Scores Big On Seattle Genetics AcquisitionCascadian Therapeutics Scores Big On Seattle Genetics Acquisition
finance.yahoo.com - February 1 at 9:15 AM
Raymond James Financial Lowers Cascadian Therapeutics (CASC) to Market PerformRaymond James Financial Lowers Cascadian Therapeutics (CASC) to Market Perform
www.americanbankingnews.com - January 31 at 5:34 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Cascadian Therapeutics, Inc. to Seattle Genetics, Inc. for $10.00 Per Share is Fair to ShareholdersSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Cascadian Therapeutics, Inc. to Seattle Genetics, Inc. for $10.00 Per Share is Fair to Shareholders
finance.yahoo.com - January 31 at 4:26 PM
BRIEF-Seattle Genetics Says If Deal Terminated Under, Cascadian Therapeutics To Pay Fee Of $17 MillionBRIEF-Seattle Genetics Says If Deal Terminated Under, Cascadian Therapeutics To Pay Fee Of $17 Million
www.reuters.com - January 31 at 9:25 AM
Seattle Genetics To Buy Cascadian Therapeutics; Sees Higher Q4 RevenuesSeattle Genetics To Buy Cascadian Therapeutics; Sees Higher Q4 Revenues
www.nasdaq.com - January 31 at 9:25 AM
Cascadians stock rockets to pace premarket gainers after Seattle Genetics buyout dealCascadian's stock rockets to pace premarket gainers after Seattle Genetics buyout deal
www.marketwatch.com - January 31 at 9:25 AM
Cascadian (CASC) Alert: Johnson Fistel Investigates Proposed Sale of Cascadian Therapeutics, Inc.; Is $10.00 a Fair Price for Shareholders?Cascadian (CASC) Alert: Johnson Fistel Investigates Proposed Sale of Cascadian Therapeutics, Inc.; Is $10.00 a Fair Price for Shareholders?
finance.yahoo.com - January 31 at 9:25 AM
Cascadian Therapeutics Inc (CASC) Short Interest Down 36.2% in JanuaryCascadian Therapeutics Inc (CASC) Short Interest Down 36.2% in January
www.americanbankingnews.com - January 29 at 1:20 AM
Critical Comparison: Cascadian Therapeutics (CASC) versus Regenxbio (RGNX)Critical Comparison: Cascadian Therapeutics (CASC) versus Regenxbio (RGNX)
www.americanbankingnews.com - January 28 at 5:18 AM
 Analysts Expect Cascadian Therapeutics Inc (CASC) to Announce -$0.29 Earnings Per Share Analysts Expect Cascadian Therapeutics Inc (CASC) to Announce -$0.29 Earnings Per Share
www.americanbankingnews.com - January 27 at 5:20 PM
Cascadian Therapeutics Inc (CASC) Receives Average Rating of "Hold" from AnalystsCascadian Therapeutics Inc (CASC) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 16 at 3:38 AM
Zacks: Brokerages Anticipate Cascadian Therapeutics Inc (CASC) to Post -$0.29 Earnings Per ShareZacks: Brokerages Anticipate Cascadian Therapeutics Inc (CASC) to Post -$0.29 Earnings Per Share
www.americanbankingnews.com - January 10 at 5:30 PM
Cascadian Therapeutics (CASC) Rating Lowered to Sell at Zacks Investment ResearchCascadian Therapeutics (CASC) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 9 at 8:12 PM
Cascadian Therapeutics (CASC) Announces 2018 OutlookCascadian Therapeutics (CASC) Announces 2018 Outlook
www.streetinsider.com - January 4 at 5:12 PM
Cascadian Therapeutics Announces 2018 Outlook and Recent ProgressCascadian Therapeutics Announces 2018 Outlook and Recent Progress
finance.yahoo.com - January 4 at 9:36 AM
Array BioPharma To Present At The Annual J.P. Morgan Healthcare ConferenceArray BioPharma To Present At The Annual J.P. Morgan Healthcare Conference
www.prnewswire.com - January 2 at 6:29 PM
BRIEF-Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver From The European Medicines AgencyBRIEF-Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver From The European Medicines Agency
www.reuters.com - January 2 at 6:29 PM
Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency - GlobeNewswire (press release)Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency - GlobeNewswire (press release)
globenewswire.com - January 2 at 9:35 AM
Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines AgencyCascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency
finance.yahoo.com - January 2 at 9:35 AM
BRIEF-Cascadian Therapeutics Files For Mixed Shelf Of Up To $250 MlnBRIEF-Cascadian Therapeutics Files For Mixed Shelf Of Up To $250 Mln
www.reuters.com - December 29 at 5:08 PM
-$0.29 EPS Expected for Cascadian Therapeutics Inc (CASC) This Quarter-$0.29 EPS Expected for Cascadian Therapeutics Inc (CASC) This Quarter
www.americanbankingnews.com - December 25 at 3:26 AM
Cascadian Therapeutics Inc (CASC) Receives Consensus Rating of "Hold" from AnalystsCascadian Therapeutics Inc (CASC) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - December 22 at 3:28 AM
Cascadian Therapeutics Added to the Nasdaq Biotechnology Index ... - GlobeNewswire (press release)Cascadian Therapeutics Added to the Nasdaq Biotechnology Index ... - GlobeNewswire (press release)
globenewswire.com - December 14 at 5:44 PM
Cascadian Therapeutics subleases big chunk of CTI BioPharmas waterfront HQCascadian Therapeutics subleases big chunk of CTI BioPharma's waterfront HQ
www.bizjournals.com - December 7 at 5:37 PM
Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast CancerProlonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer
finance.yahoo.com - December 7 at 5:37 PM
 Brokerages Anticipate Cascadian Therapeutics, Inc. (CASC) Will Post Earnings of -$0.29 Per Share Brokerages Anticipate Cascadian Therapeutics, Inc. (CASC) Will Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - December 7 at 11:32 AM
Cascadian, Potential Catalysts, Recent Highlights, Tucatinib UpdateCascadian, Potential Catalysts, Recent Highlights, Tucatinib Update
finance.yahoo.com - November 28 at 8:22 AM
Cascadian Therapeutics, Inc. (CASC) Receives Consensus Rating of "Hold" from AnalystsCascadian Therapeutics, Inc. (CASC) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - November 27 at 3:46 AM
Array BioPharma To Present At The 2017 Piper Jaffray Healthcare ConferenceArray BioPharma To Present At The 2017 Piper Jaffray Healthcare Conference
www.prnewswire.com - November 22 at 5:44 PM
Cascadian Therapeutics: Upside In Other Her2+ Indications - Seeking AlphaCascadian Therapeutics: Upside In Other Her2+ Indications - Seeking Alpha
seekingalpha.com - November 21 at 5:09 PM
-$0.29 Earnings Per Share Expected for Cascadian Therapeutics, Inc. (CASC) This Quarter-$0.29 Earnings Per Share Expected for Cascadian Therapeutics, Inc. (CASC) This Quarter
www.americanbankingnews.com - November 19 at 3:26 PM
Cascadian Therapeutics, Inc. (CASC) Stock Rating Lowered by Zacks Investment ResearchCascadian Therapeutics, Inc. (CASC) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - November 14 at 5:58 PM
Cascadian Therapeutics, Inc. (CASC) Upgraded to Buy by Zacks Investment ResearchCascadian Therapeutics, Inc. (CASC) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - November 13 at 6:30 PM
Cascadian Therapeutics, Inc. (CASC) Releases Quarterly  Earnings Results, Beats Estimates By $0.01 EPSCascadian Therapeutics, Inc. (CASC) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - November 9 at 5:44 PM
Edited Transcript of CASC earnings conference call or presentation 8-Nov-17 9:30pm GMTEdited Transcript of CASC earnings conference call or presentation 8-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 6:01 AM
Cascadian Therapeutics Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)Cascadian Therapeutics Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 8 at 7:53 PM

SEC Filings

Cascadian Therapeutics (NASDAQ:CASC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cascadian Therapeutics (NASDAQ:CASC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cascadian Therapeutics (NASDAQ CASC) Stock Chart for Saturday, February, 17, 2018

Loading chart…

This page was last updated on 2/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.